Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Why Is My Budget Not Working helps you pinpoint where spending misaligns with goals and how to adjust for consistent progress.
27,172 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A little-known international ETF is quietly outperforming the S&P 500 this year, riding a multi-factor strategy and l...
Barclays slashed Coinbase’s price target to $107 following aQ1 2026 revenue miss, highlighting a tug-of-war between c...
Alphabet is tightening the gap with Nvidia as AI wins bolster its diversified business empire. Investors weigh the im...
Mizuho raises Dell's price target to $300 on expected durable demand from agentic AI servers, while UBS nudges valuat...
Investors eyeing mdxhealth (mdxh) 2026 earnings will focus on adoption rates, reimbursement, and partnerships. This g...
Strategy unveils a private repurchase of roughly $1.5 billion in convertible notes, funded by cash, ATM proceeds, and...
As U.S. markets face volatility, a single low-cost ETF offering broad exposure to Europe and Japan is drawing steady ...
The latest RealTrends verification highlights 2026 GameChangers who turned market disruption into rapid expansion, le...
Ripple vaults onto CNBC’s disruptor list, while XRP trades in a tight range. The token hovered around $1.35 as market...
Micron reports robust Q3 guidance and signs a five-year strategic deal, fueling optimism that the AI memory cycle cou...
Three leading space names moved higher in a risk-on trading session, with AST SpaceMobile, Rocket Lab and Planet Labs...